Gule The white-nosed coati Nasua narica is a naturally susceptible definitive host for the zoonotic nematode Angiostrongylus costaricensis in Costa Rica. Cases 3 and 4 illustrate the presumptive and probable diagnoses of less severe forms of HAA, angioztrongylus solely on abdominal symptoms and marked eosinophilia. Christopher Swale and Prof. Peru [ 60 ]. Computerized axial tomography, Dx: This invasive species, first described in in Martinique, is responsible for the emergence of central nervous system angiostrongyliasis due to Angiostrongylus cantonensis in the Lesser Antilles [ 9 ]. Surgery can solve ischemia-related intestinal damage and perforation.
|Published (Last):||4 November 2013|
|PDF File Size:||8.31 Mb|
|ePub File Size:||9.9 Mb|
|Price:||Free* [*Free Regsitration Required]|
Diagnosis Angiostrongylus cantonensis A diagnosis of A. History of ingestion of raw or undercooked intermediate hosts or possibly transport hosts is a crucial clue as well. However, ill persons may not be aware of ingestion of foods that could lead to infection. It is important to note, however, that eosinophilia in the CSF and in the blood may not be present on initial presentation or in late stages of infection. The CSF pressure is generally elevated. Recovery of A. Serologic tests have been developed but are not commercially available.
A few specialty or research laboratories offer serologic tests, but the sensitivity and specificity of the tests may not be optimal and the infection is often identified only on convalescent sera. Because of the difficulty in making the diagnosis, it is important to rule-out other causes of eosinophilic meningitis. Neuroimaging studies can be useful as there usually is an absence of focal lesions on CT scan, which helps to distinguish A.
Because eggs are not passed in the feces, a stool examination is not useful for diagnosis. Angiostrongylus costaricensis Although several serologic tests have been developed by researchers, they are not readily available. Cases are often diagnosed postoperatively by examination of surgical specimens.
Radiologic examination of the gastrointestinal tract may demonstrate edema and spasticity in the areas of inflammation. The parasitic differential diagnosis includes anisakiasis and toxocariasis.
Treatment Angiostrongylus cantonensis Treatment is usually supportive with the use of analgesics for pain and corticosteroids to limit the inflammatory reaction. Careful removal of CSF at frequent intervals can help to relieve headache in patients with elevated intracranial pressure.
No anthelminthics drugs have been proven to be effective in treatment, and there is concern that anthelminthics could exacerbate neurological symptoms due to a systemic response to dying worms. The effectiveness of any regimen may vary by endemic region. One randomized, placebo-control study of a 2-week course of prednisolone 60 mg per day in 3 divided doses found that the corticosteroids reduced the median length of headache from 13 days to 5 days and reduced the need for repeat lumbar puncture.
Additionally 9. As there was no control group, it is difficult to determine if the anthelminthic provided additional benefit.
Comparing the results from the placebo-control trial to the 2 case-series, 9. One small trial that directly compared prednisolone monotherapy to prednisolone-albendazole combined therapy found no benefit of adding albendazole to the regimen.
Additional symptomatic treatment may also be required for nausea, vomiting, and in some cases chronic pain due to nerve damage and muscle atrophy. Angiostrongylus costaricensis There is no proven treatment for illness caused by A. Acute episodes may resolve spontaneously or require surgical treatment for intestinal inflammation. Data on the use of mebendazole in pregnant women are limited. The available evidence suggests no difference in congenital anomalies in the children of women who were treated with mebendazole during mass treatment programs compared with those who were not.
In mass treatment programs for which the World Health Organization WHO has determined that the benefit of treatment outweighs the risk, WHO allows use of mebendazole in the 2nd and 3rd trimesters of pregnancy. The risk of treatment in pregnant women who are known to have an infection needs to be balanced with the risk of disease progression in the absence of treatment. Pregnancy Category C: Either studies in animals have revealed adverse effects on the fetus teratogenic or embryocidal, or other and there are no controlled studies in women or studies in women and animals are not available.
Drugs should be given only if the potential benefit justifies the potential risk to the fetus. Note on Treatment During Lactation It is not known whether mebendazole is excreted in breast milk.
The WHO classifies mebendazole as compatible with breastfeeding and allows the use of mebendazole in lactating women. Note on Treatment in Pediatric Patients The safety of mebendazole in children has not been established. There is limited data in children age 2 years and younger. Mebendazole is listed as an intestinal antihelminthic medicine on the WHO Model List of Essential Medicines for Children, intended for the use of children up to 12 years of age.
Data on the use of albendazole in pregnant women are limited, though the available evidence suggests no difference in congenital abnormalities in the children of women who were accidentally treated with albendazole during mass prevention campaigns compared with those who were not. In mass prevention campaigns for which the World Health Organization WHO has determined that the benefit of treatment outweighs the risk, WHO allows use of albendazole in the 2nd and 3rd trimesters of pregnancy.
However, the risk of treatment in pregnant women who are known to have an infection needs to be balanced with the risk of disease progression in the absence of treatment. Note on Treatment During Lactation It is not known whether albendazole is excreted in human milk. Albendazole should be used with caution in breastfeeding women.
Note on Treatment in Pediatric Patients The safety of albendazole in children less than 6 years old is not certain. Studies of the use of albendazole in children as young as one year old suggest that its use is safe. According to WHO guidelines for mass prevention campaigns, albendazole can be used in children as young as 1 year old. Many children less than 6 years old have been treated in these campaigns with albendazole, albeit at a reduced dose.
Page last reviewed: August 28,
Resources for Health Professionals
Pathology[ edit ] Pathology is due to both the adults and the eggs. Adults in the ileo-caecal arterioles cause an inflammatory eosinophilic response in humans. In the Cotton Rat the adult worms cause local haemorrhages. The intestinal wall is also affected. In humans there is a thickening of the intestinal wall ileum, appendix and caecum.